Analysts Expect ContraFect Corp (CFRX) to Announce ($0.11) Earnings Per Share
Shares of ContraFect Corp (NASDAQ:CFRX) have earned a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that cover the stock, Zacks Investment Research reports. Four research analysts have rated the stock with a strong buy recommendation.
Brokerages have set a twelve-month consensus target price of $2.63 for the company and are anticipating that the company will post ($0.11) earnings per share for the current quarter, according to Zacks. Zacks has also given ContraFect an industry rank of 47 out of 255 based on the ratings given to its competitors.
Institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. increased its stake in shares of ContraFect by 108.1% during the third quarter. JPMorgan Chase & Co. now owns 167,182 shares of the biotechnology company’s stock worth $346,000 after acquiring an additional 86,848 shares during the period. Renaissance Technologies LLC increased its stake in shares of ContraFect by 109.8% during the third quarter. Renaissance Technologies LLC now owns 420,700 shares of the biotechnology company’s stock worth $871,000 after acquiring an additional 220,200 shares during the period. Federated Investors Inc. PA increased its stake in shares of ContraFect by 6.8% during the third quarter. Federated Investors Inc. PA now owns 6,407,500 shares of the biotechnology company’s stock worth $13,264,000 after acquiring an additional 407,500 shares during the period. Vanguard Group Inc increased its stake in shares of ContraFect by 24.2% during the third quarter. Vanguard Group Inc now owns 2,634,428 shares of the biotechnology company’s stock worth $5,454,000 after acquiring an additional 512,940 shares during the period. Finally, Trellus Management Company LLC increased its stake in shares of ContraFect by 43.7% during the fourth quarter. Trellus Management Company LLC now owns 120,676 shares of the biotechnology company’s stock worth $185,000 after acquiring an additional 36,721 shares during the period. Institutional investors and hedge funds own 55.57% of the company’s stock.
ContraFect (NASDAQ:CFRX) last issued its quarterly earnings results on Thursday, March 14th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.17. As a group, sell-side analysts expect that ContraFect will post -0.38 earnings per share for the current year.
ContraFect Company Profile
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
Further Reading: What is a portfolio manager?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.